Renalytix Plc participated at the American Diabetes Association (ADA) 82nd Scientific Sessions® meeting in New Orleans from June 3-7, 2022. There were two data presentations focused on the value of KidneyIntelX in care for adult patients with type 2 diabetes (T2D) and early-stage chronic kidney disease (CKD), including a late-breaking ePoster and an oral presentation. KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix.

Mount Sinai and Mount Sinai faculty, including Dr. Coca, have a financial interest in Renalytix. Mount Sinai also has representation on the Renalytix Board of Directors.